-
Syfovre Case Report: Occlusive Retinal Vasculitis Shortly After Patient’s First Syfovre Injection
Pre-Existing Allergy Toward Polyethylene Glycol (PEG) is Most Recent Causation Theory Offered by Apellis (Posted by Tom Lamb at Drug Injury Watch) In late January 2024, a leading medical journal for ophthalmologists and retina specialists,…
-
“New” Blood Clots Side Effect of Semaglutide Weight Loss Drugs Like Ozempic: Deep Vein Thrombosis
Research Finding: Semaglutide Increased the Risk of Deep Vein Thrombosis (DVT) by 266% in Patients with Type 2 Diabetes (Posted by Tom Lamb at Drug Injury Watch) UPDATE No Warnings About Blood Clots From Ozempic,…
-
Gastroparesis Case Reports Involving the Use of GLP-1 Receptor Agonists Semaglutide and Dulaglutide
Learn About Related Symptoms and Diagnosis Process for Gastroparesis, a Side Effect of Ozempic, Wegovy, Rybelsus, and Trulicity (Posted by Tom Lamb at Drug Injury Watch) In this article, we present some gastroparesis case reports…
-
Prolia Increased Risk Of Hypocalcemia In Patients With Chronic Kidney Disease (CKD) Can Be 20-Times Higher Than Pills
Prolia "Black Box" Warning: Harm From Severe Hypocalcemia Ranges From Hospitalization For Life-threatening Events To Death (Posted by Tom Lamb at Drug Injury Watch) A January 2024 JAMA Original Investigation article, "Severe Hypocalcemia With Denosumab…
-
Syfovre Safety Issues Need More Attention Before This Relatively New Eye Drug Gets Widely Prescribed
December 2023 JAMA Ophthalmology Viewpoint Piece About Syfovre Calls for Independent and Unbiased Evaluation (Posted by Tom Lamb at Drug Injury Watch) UPDATE: From this February 28, 2024, Fierce Pharma news report, "Apellis cites current challenges with…
-
Syfovre Update: New Warnings About Retinal Vasculitis and/or Retinal Vascular Occlusion After Syfovre Injections
November 2023 Syfovre Label Change Comes After Earlier Reports of Eye Inflammation and Severe Vision Loss (Posted by Tom Lamb at Drug Injury Watch) UPDATE: From this February 28, 2024, Fierce Pharma news report, "Apellis cites…